Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
23 results
D3.344 - Biological therapy for severe chronic spontaneous urticaria associated with autoimmune atrophic gastritis
D3.348 - A Case of 19p13.3 Microdeletion
D3.349 - Evaluation of natural killer cells in female infertility
D3.351 - Characterization of peanut roasting-enhanced Ara h 2 - Ara h 1 complexes
D3.345 - Blood Dendritic Cell Antigen 3-Positive Dendritic Cells Attenuate Th2 Responses in Allergic Rhinitis and Chronic Rhinosinusitis
D3.346 - Impact of local craniocerebral hypothermia on inflammatory cytokine production in ischemic stroke
D3.347 - AllergoOncology: a systematic review of the impact of glycosylation on IgE antibody structure function and mechanisms of disease
D3.350 - Monocytic myeloid-derived suppressor cells (M-MDSCs) increase the expression of TIGIT on γδ T cells
D3.353 - An EAACI Task Force Scoping Review: Human Monocytes and Macrophages in Allergy – Implications for AllergoOncology
D3.354 - Selective IgE deficiency in children: its role in autoimmunity
D3.355 - Decoupling of total IgE and peripheral blood eosinophilia in pancreatic ductal adenocarcinoma: preliminary study
D3.356 - Unconventional T cells in leukocyte adhesion deficiency I (LAD-I)
D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data
D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases
D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin
D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity
D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis
D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes
D3.416 - Hereditary Alpha-Tryptasemia: A Case Series
D3.417 - "Comprehensive Allergological Evaluation and Management of Severe Anaphylaxis to Vespid Venoms: A Case Study"
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download